Compare FTAI Aviation Ltd (FTAI) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Gilead Sciences, Inc. — how do they compare? FTAI Aviation Ltd trades at $201.36 (market cap $21.93B), while Gilead Sciences, Inc. trades at $133.44 (market cap $163.51B). The key difference: Gilead Sciences, Inc. is far larger — about 7.5× FTAI Aviation Ltd's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| FTAI | GILD | |
|---|---|---|
Market Cap | $21.93B | $163.51B |
Sector | Industrials | Health |
52-Week High | $310.04 | $155.80 |
52-Week Low | $109.92 | $108.22 |
Enterprise Value | $24.97B | $178.05B |
Dividend Yield | 0.7% | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
